Reglitazar

Drug Profile

Reglitazar

Alternative Names: JTT 501; PNU 182716; PNU 716; reglixane

Latest Information Update: 20 Jan 2003

Price : $50

At a glance

  • Originator Japan Tobacco
  • Developer Japan Tobacco; Pharmacia Corporation
  • Class Antihyperglycaemics; Insulin sensitisers
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 24 Oct 2002 Discontinued - Phase-II for Diabetes mellitus in Japan (unspecified route)
  • 24 Oct 2002 Discontinued - Phase-II for Diabetes mellitus in USA (unspecified route)
  • 08 Nov 2001 Reglitazar is the pINN for PNU 716
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top